BIOMEDE 2.0 trial for DIPG and similar brainstem gliomas
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This phase 3 study tests targeted treatments (ONC201 or everolimus) for children with DIPG or similar diffuse midline brain tumors, based on the tumor’s genetic markers. It aims to improve outcomes by matching treatment to the tumor biology and comparing approaches in a randomized way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with DIPG, or a closely related diffuse midline glioma
- There must be tumor tissue or fluid/blood testing available to check specific tumor markers (or a biopsy plan is possible)
- Your child is older than 6 months (no upper age limit, but very young kids may be considered case-by-case)
- The tumor can be treated with brain or craniospinal radiotherapy as part of the plan
- No prior chemotherapy for this cancer, and no prior radiation to the brainstem
- You (and your child, if able) can sign the consent/assent and follow the study visits closely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.